Figure 3
Outcome to bevacizumab-containing therapy in CRC by serum Ang-2 (n=34). (A) Response by serum Ang-2. (B) PFS by serum Ang-2. (C) OS by serum Ang-2. Ang-2, angiopoietin-2.
Figure 3 | British Journal of Cancer
Outcome to bevacizumab-containing therapy in CRC by serum Ang-2 (n=34). (A) Response by serum Ang-2. (B) PFS by serum Ang-2. (C) OS by serum Ang-2. Ang-2, angiopoietin-2.
